GHRH (Sermorelin 1-44)
Overview
Sermorelin is a synthetic 44-amino acid peptide corresponding to the biologically active portion of human growth hormone releasing hormone (GHRH). It stimulates endogenous growth hormone secretion from the anterior pituitary by binding to GHRH receptors. Originally approved for diagnostic testing of growth hormone secretion, sermorelin was subsequently marketed for treatment of growth hormone deficiency in children before being voluntarily withdrawn.
Key Research Findings
FDA approval was granted in 1997 under the brand name Geref for diagnostic use and later extended to therapeutic indications in pediatric growth hormone deficiency. The manufacturer discontinued sermorelin acetate in the mid-2000s for business reasons unrelated to safety or efficacy. Clinical evidence demonstrated physiologic growth hormone stimulation, though it has been largely supplanted by recombinant growth hormone products.
Subcutaneous injection
Investigational
Interested in GHRH (Sermorelin 1-44)?
Find a verified provider experienced with GHRH (Sermorelin 1-44) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a GHRH (Sermorelin 1-44) ProviderRelated Peptides
CJC-1295
In Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, extending its half-life from minutes to approximately 6-8 days. CJC-1295 stimulates pulsatile GH release from the anterior pituitary by binding to GHRH receptors while preserving the natural GH secretory pattern and negative feedback mechanisms.
Ipamorelin
In Clinical TrialsA highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH release. Unlike other GH secretagogues, ipamorelin does not significantly affect ACTH, cortisol, or prolactin levels, making it one of the most specific GH-releasing peptides. It works synergistically with GHRH analogs like CJC-1295.
Sermorelin
FDA ApprovedA synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid hormone. Sermorelin stimulates the pituitary to produce and release growth hormone through the natural GHRH receptor pathway, preserving the hypothalamic-pituitary feedback axis. It maintains physiological pulsatile GH secretion patterns.
Tesamorelin (Egrifta)
FDA ApprovedA synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability. Tesamorelin specifically targets visceral adipose tissue reduction by stimulating lipolysis through GH-mediated pathways. It is the only FDA-approved treatment for HIV-associated lipodystrophy.